AnaptysBio Inc. (NASDAQ: ANAB) stock jumped 0.16% on Tuesday to $25.17 against a previous-day closing price of $25.13. With 1.52 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.25 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $25.44 whereas the lowest price it dropped to was $24.60. The 52-week range on ANAB shows that it touched its highest point at $34.33 and its lowest point at $18.20 during that stretch. It currently has a 1-year price target of $32.12. Beta for the stock currently stands at -0.11.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ANAB was down-trending over the past week, with a drop of -1.22%, but this was down by -12.88% over a month. Three-month performance dropped to -8.87% while six-month performance rose 17.02%. The stock lost -18.78% in the past year, while it has lost -18.78% so far this year. A look at the trailing 12-month EPS for ANAB yields -4.83 with Next year EPS estimates of -4.38. For the next quarter, that number is -0.97. This implies an EPS growth rate of -188.60% for this year and 5.60% for next year.
Float and Shares Shorts:
At present, 28.43 million ANAB shares are outstanding with a float of 28.34 million shares on hand for trading. On Oct 13, 2022, short shares totaled 5.49 million, which was 19.45% higher than short shares on Sep 14, 2022. In addition to Mr. Daniel R. Faga as the firm’s Interim Pres & CEO and Director, Mr. Eric J. Loumeau serves as its COO & Gen. Counsel.
Through their ownership of 121.87% of ANAB’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 75.78% of ANAB, in contrast to 43.98% held by mutual funds. Shares owned by individuals account for 32.60%. As the largest shareholder in ANAB with 26.45% of the stake, Ecor1 Capital LLC holds 7,521,024 shares worth 7,521,024. A second-largest stockholder of ANAB, Tang Capital Management LLC, holds 2,628,678 shares, controlling over 9.25% of the firm’s shares. Point72 Asset Management LP is the third largest shareholder in ANAB, holding 2,526,200 shares or 8.89% stake. With a 4.17% stake in ANAB, the Federated Hermes Kaufmann Small C is the largest stakeholder. A total of 1,185,830 shares are owned by the mutual fund manager. The Federated Hermes Kaufmann Fund, which owns about 3.93% of ANAB stock, is the second-largest Mutual Fund holder. It holds 1,117,802 shares valued at 34.64 million. SPDR S&P Biotech ETF holds 2.42% of the stake in ANAB, owning 689,084 shares worth 21.35 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ANAB since 6 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ANAB analysts setting a high price target of $44.00 and a low target of $28.00, the average target price over the next 12 months is $33.17. Based on these targets, ANAB could surge 74.81% to reach the target high and rise by 11.24% to reach the target low. Reaching the average price target will result in a growth of 31.78% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ANAB will report FY 2022 earnings on 03/04/2024. Analysts have provided yearly estimates in a range of -$4.30 being high and -$4.83 being low. For ANAB, this leads to a yearly average estimate of -$4.63. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. AnaptysBio Inc. surprised analysts by -$0.56 when it reported -$1.18 EPS against a consensus estimate of -$0.62. The surprise factor in the prior quarter was -$0.17. Based on analyst estimates, the high estimate for the next quarter is -$0.66 and the low estimate is -$1.11. The average estimate for the next quarter is thus -$0.97.
Summary of Insider Activity:
Insiders traded ANAB stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 3 while that of sell transactions has risen to 4 over the past year. The total number of shares bought during that period was 1,557,780 while 672,406 shares were sold.